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Abstract. Laminin-2 is a component of skeletal and 
cardiac basal lamina expressed in normal mouse and 
human. Laminin or2 chain (LAMA2), however, is ab- 
sent from muscles of some congenital muscular dystro- 
phy patients and the dystrophia muscularis (dy/dy) 
mouse model. LAMA2 restoration was investigated 
following cell transplantation in vivo in dy/dy mouse. 
Allogeneic primary muscle cell cultures expressing the 
13-galactosidase transgene under control of a muscular 
promoter, or histocompatible primary muscle cell cul- 
tures, were transplanted into dy/dy mouse muscles. 
FK506 immunosuppression was used in noncompatible 
models. All transplanted animals expressed LAMA2 in 
these immunologicaUy-controlled  models, and the de- 
grees of LAMA2 restoration were shown to depend on 
the age of the animal at transplantation, on muscle pre- 
treatment, and on duration time after transplantation in 
some cases. LAMA2 did not always colocalize with 
new or hybrid muscle fibers formed by the fusion of do- 
nor myoblasts. LAMA2 deposition around muscle fi- 
bers was often segmental and seemed to radiate from 
the center to the periphery of the injection site. Alloge- 
neic conditionally  immortalized pure myogenic cells 
expressing the 13-galactosidase transgene were charac- 
terized in vitro and in vivo. When injected into FK506- 
immunosuppressed dy/dy mice, these cells formed new 
or hybrid muscle fibers but essentially did not express 
LAMA2 in vivo. These data show that partial LAMA2 
restoration is achieved in LAMA2-deficient dy/dy 
mouse by primary muscle cell culture transplantation. 
However, not all myoblasts, or myoblasts alone, or the 
muscle fibers they form are capable of LAMA2 secre- 
tion and deposition in vivo. 
AMININ-2 belongs  to the laminin family (Burgeson et 
al., 1994) and is present in basal laminae of cardiac 
and skeletal muscle cells (Ehrig et al., 1990). Some 
cells of mesenchymal origin,  Schwann  cells, and thyroid 
cells would participate in its secretion (Leivo and Engvall, 
1988; Engvall, 1993; Andre et al., 1994). Laminin-2 is con- 
stituted by the assembly of three subunits called et2 chain 
(400 kD), 131, and ~1 chains (200 kD each). Laminins have 
cross-like three-dimensional structures which interact with 
cellular receptors such as integrins (Engvall,  1993). Lami- 
nin-2 interacts with the 156-kD dystrophin-associated gly- 
coprotein (o~-dystroglycan;  Campbell,  1995). The laminins 
promote cell  spreading,  migration, proliferation, and/or 
differentiation, and laminin-2  also promotes neurite out- 
growth  and  nerve-muscle  interactions  (Engvall  et  al., 
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1992). Laminin or2 chain (LAMA2)  1  also promotes Schwann 
cell migration in vitro and nerve regeneration in vivo (An- 
ton et al., 1994). The gene coding for human ct2 chain has 
been cloned and located on chromosome 6 in position q22/ 
23. The cDNA is about 9.5 kb in length and encodes for a 
more than 3,100-amino  acid protein (Vuolteenaho et al., 
1994). 
Hayashi et al. (1993) showed that the LAMA2 expres- 
sion was reduced in muscle cell basal membranes of some 
Fukuyama-type congenital muscular dystrophy patients, 
and Tom6 et al. (1994) showed that LAMA2 expression 
was deficient in  13  of 20 congenital muscular dystrophy 
(CMD) patients (i.e., 65%).  Out of 25 CMD patients, Se- 
wry et al. (1995) also showed that LAMA2 expression was 
undetectable in seven and reduced to trace amounts in 
five. Thus, 48% of CMD patients in this series were defi- 
cient for LAMA2 expression. The LAMA2 deficiency has 
been linked to the Lama2 gene on chromosome 6 (Hillaire 
1. Abbreviations used in this paper: 13-gal, 13-galactosidase; CMD, congeni- 
tal muscular dystrophy; IFN-~,, interferon ~/; LAMA2, laminin-2 et2 chain; 
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the development of the LAMA2-negative CMD has been 
reported  in  man  (Helbling-Leclerc  et  al.,  1995).  One 
LAMA2-negative CMD patient also presented LAMA2 
mRNA deficiency (Hayashi et al.,  1995).  The LAMA2- 
deficient CMD patients usually have a more severe clinical 
phenotype  than  LAMA2-positive  CMD  patients.  They 
regularly present white matter changes on brain imaging 
(Philpot et al., 1995).  The identification of mutations on 
the Lama2 gene could provide a useful tool in categorizing 
various CMD which show clinical heterogeneity (for re- 
view see Dubowitz and Fardeau, 1995; Helbling-Leclerc et 
al., 1995). The Fukuyama-type CMD would not be directly 
linked to the Lama2 gene. 
Three  groups  showed  that  the  dystrophia  muscularis 
(dy/dy)  mouse model was deficient for LAMA2 expres- 
sion (Arahata et al., 1993; Sunada et al., 1994; Xu et al., 
1994a). In these studies, LAMA2 was undetectable in im- 
munohistofluorescence in skeletal and cardiac muscle cell 
basement membranes and in peripheral nerve and some 
very low levels of LAMA2 mRNA could be detected only 
after RT-PCR amplification (Arahata et al., 1993; Xu et 
al., 1994a). The LAMA2 deficiency has been linked to the 
Lama2 gene on chromosome 10 in dy/dy mouse (Sunada 
et al., 1994) and a mutation has been identified in the dye~ 
dy  2s mouse, an allelic variant of the LAMA2-negative dy/ 
dy model (Xu et al., 1994b; Sunada et al., 1995). First de- 
scribed in 1955, the dy/dy mouse develops early signs of 
muscular dystrophy (Michelson et al., 1955). The progres- 
sive and lethal dystrophy is characterized first by ataxia, 
convulsive head movements, spasmodic hind leg flexion, 
and flaccid extension, followed by progressive muscle at- 
rophy and paralysis extending to  axial musculature and 
anterior legs. At the late stages, the posterior leg locomo- 
tion is lost and the mouse develops marked kyphosis. The 
size, number and diameter of muscle fibers, are  greatly 
variable  in  dy/dy  mice,  but  always less  than in  normal 
mice. The muscles are invaded by connective tissues. The 
neural system of the dy/dy  mice also show many abnor- 
malities. The Schwann cell basal lamina are patchy, and 
the myelination of the peripheral nervous system is vari- 
ably defective (Bradley and Jenkison, 1973; Madrid et al., 
1975; Montgomery and Swenarchuk, 1977). The life span 
of the dyldy mouse is rarely more than six months, and the 
disease is of autosomal recessive transmission. 
The milder allelic variant of the dy/dy mouse, the dy2S/ 
dy  2s mouse model, express a truncated protein (Xu et al., 
1994b; Sunada et al., 1995). This model would not truly re- 
flect at least the majority of the human CMD because of 
the  expression  of  a  truncated  but  partially  functional 
LAMA2.  Muscle  regeneration  was  investigated  in  the 
dy2S/dy  2s mouse following muscle tissue, G8 clonal muscle 
cells, and primary fetal or newborn muscle cell transplan- 
tations (Law, 1982; Law et al., 1988a,b).  The aetiology and 
molecular basis of this neuromuscular pathology were un- 
known at the time of these experiments and the use of this 
animal model seems now partially inadequate. Actually, 
G8 myoblasts did not form hybrid muscle fibers (Law et 
al., 1988a),  and some models were not compatible for mi- 
nor antigens (Law et al., 1988b).  Some, but few animals 
showed behavioral improvements 2 to 7 mo after trans- 
plantation (Law et al., 1988a). 
Myoblast transplantations have been performed in the 
mdx/mdx mouse,  which is  a  biochemical model of Du- 
chenne muscular dystrophy. Transplantations of cultured 
muscle cells promoted myoblast fusion, formation of new 
and/or hybrid muscle fibers in vivo, and intracellular dys- 
trophin restoration in mdxlmdx mice. One of the major 
drawbacks of myoblast transplantation experiments is the 
host immune response  against donor cells (Kinoshita et 
al.,  1994b;  Gu6rette  et  al.,  1995).  Immunosuppressive 
treatments,  immunodeficient or immunocompatible ani- 
mals, were used to overcome this problem (Partridge et 
al., 1978, 1989; Grounds et al., 1980; Watt et al., 1984; Mor- 
gan et al., 1990, 1992, 1993, 1994; Huard et al.,  1994; Ki- 
noshita et al., 1994a,b;  Pavlath et al., 1994; Asselin et al., 
1995; Vilquin et al., 1995a,c).  Our group has obtained the 
best  success  either  using FK506  immunosuppression  to 
control nonhistocompatible myoblast transplantation, or 
using fully compatible host/donor combinations (Kinosh- 
ita et al., 1994b; Vilquin et al., 1995c). 
In the present study, LAMA2 restoration in the dy/dy 
mouse  after transplantation of cultured primary muscle 
ceils was evaluated with respect to age at transplantation, 
type of transplantation, and muscle pretreatment. In addi- 
tion, pure myoblast cultures were used to study the role of 
myoblasts in LAMA2 deposition in vivo. 
Materials and Methods 
Animals 
The C57BI-d6J dy/dy mice (Jackson Laboratories, Bar Harbor, ME) were 
used as recipients for myoblast transplantation. The C57BL/6J  +/+  nor- 
mal newborn mice (Jackson Laboratories) were used as compatible do- 
nors for some myoblast transplantations. 
The transgenic TnI-LacZ1/29  mice (Tn-LacZ,  gift from K.  Hasting, 
McGill University, Montr6al, Canada) contain the LacZ gene under the 
control of the quail fast troponin I promoter, thus, myotubes and muscle 
fibers express a cytoplasmic 13-galactosidase  (13-gal) protein (HaUauer et 
al., 1993; Kinoshita et al., 1994a,b).  I~-gal expression is not restricted to the 
nucleus in this model. Both male and female parents are heterozygous an- 
imals, and newborn mice were used as donors for some immunologically 
noncompatible myoblast transplantations. 
The H-2Kb-tsA58 transgenic mice carry the thermolabile tsA58 mutant 
of SV40 large T antigen under the control of the H-2K  b promoter (Jat et 
al.,  1991).  Interferon ",/ (IFN-~/)  increases the transcription of this pro- 
moter. The thermolabile protein is functionally active at 33°C but not at 
39°C. These characteristics facilitate the derivation of conditionally im- 
mortalized cell lines (Morgan et al., 1994). An homozygous H-2Kb-tsA58 
male mouse (Charles River Lab., Wilmington, MA) was crossed with a 
heterozygous transgenic Tn-LacZ female mouse. Offsprings were all het- 
erozygous for the H-2Kb-tsA58 transgene and some were heterozygous 
for the Tn-LacZ transgene. Thus, newborns were tested for 13-gal expres- 
sion, and only 13-gal positive animals were used for the establishment of 
myogenic cell lines (see below), 
Primary Cell Cultures 
Mouse primary myoblast cultures were obtained from biopsies from new- 
born skeletal muscle as previously described (Vilquin et al., 1995c). The 
cell suspension was cultured in 199 medium (GIBCO BRL, Gaithersberg, 
MD) supplemented with 15% FBS (GIBCO BRL) and antibiotics. Cells 
were harvested at 70% confluence, that is, 2 d after plating, either for im- 
mediate grafting or for freezing until grafting. These cultures were not 
pure and contained several cell types, with 30-40% being commited myo- 
blasts as assessed by desmin immunostaining (personal results). 
Cultures were also obtained from newborn transgenic Tn-LacZ. Be- 
cause parents were both heterozygous, newborns were individually tested 
for the expression of 13-gal using X-gal (see below). Only 13-gal-positive 
newborns were used for primary myoblast cultures. 
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Figure 1.  Transplantation  models used in this study. 
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Different batches of primary cell cultures have been used for this work. 
The mice transplanted with these batches have been gathered under the 
letters A, B (13-gal cells), and H  (histocompatible cells). 
Establishment of  Permanent Myogenic Cell Lines from 
(TnI-LacZl129) × (H-2I~-tsA58) Offsprings 
Primary muscle cell  cultures were  started  using the  13-gal-positive off- 
springs. Following preplating, the cells were plated at 50 cells/cm: in gela- 
tin-coated wells and grown in DME (GIBCO BRL) supplemented with 
20% FCS and 2% chick embryo extract (GIBCO BRL) at 33~C in 10% 
CO:.  Mouse recombinant IFN-  7  (Genzyme Co.,  Cambridge, MA)  was 
added at the final concentration of 20 U/ml (Morgan et al., 1994).  Colo- 
nies of typical myogenic morphology were subsequently cloned in 96-well 
plates at the limit dilution of one cell per well. The myogenicity of colo- 
nies and clones was assessed by desmin immunostaining and by the ability 
to fuse and form myotubes in vitro. Fusion was obtained by reducing the 
FCS concentration to 5% and growing the cells at 37°C in 5% CO: in the 
absence of IFN-~/. 
Permanent Fibroblast Cell Lines 
Permanent  fibroblast  cell  lines  $3T3  and  BLK  CL.4  were  both  from 
American Type Culture Collection (Rockville, MD). 
Cell Transplantation 
On the day of transplantation, the cells were harvested by trypsinization 
or thawing, washed three times in HBSS  (GIBCO  BRL),  and concen- 
trated as pellets. Cell viability was assessed using trypan blue staining. The 
Tibialis  anterior  (TA) muscles were exposed and injected with approxi- 
mately 4  ×  106 (primary muscle cell cultures), or 106 (myogenic cell lines 
No. 24, MB7, MB27) or 3  ×  106 (myogenic cell line MB3, fibroblast cell 
lines $3T3, and BLK CL.4) viable cells suspended in 10 Ixl of HBSS. When 
the role of myoblasts in LAMA2 restoration was explored by clonal cell 
transplantation, the left TA of the mouse received only myogenic clones, 
while the right TA received both myogenic clones and a histocompatible 
primary muscle cell culture  (i.e.,  obtained  from normal C57BL6J  +/+ 
newborn  mice).  Some  protocols  included  v-irradiation  and/or  notexin 
treatment of the muscles before cell transplantation: three days before 
transplantation, one or both hind legs of the dy/dy mice were Cobalt-irra- 
diated  (20 Gy).  This level of irradiation has been shown to  block  host 
myoblast proliferation and to favor donor myoblast implantation (Wirtz 
et al., 1982; Morgan et al., 1990; Wakeford et al., 1991);  one day before 
transplantation, one or both TA were exposed and injected with 10 Ixl of 
notexin venom (5 p~g/ml), which has been shown to trigger muscle fiber 
degeneration without damaging myoblasts (Harris et al., 1975). FK506 im- 
munosuppression  was started on the day of transplantation in noncompat- 
ible  grafting models (2.5 mg/kg/d i.m.; Fujisawa Co,  Osaka, Japan; Ki- 
noshita et  al.,  1994b).  The  transplantation  schedules are  presented  in 
Fig. 1. 
Muscle Collection 
At the times indicated, the TA muscles were collected and immersed in a 
sucrose solution (Tremblay et al., 1993).  Muscles were embedded, frozen 
in liquid nitrogen, and serially sectioned at 8 p,m. Adjacent serial sections 
were thus spaced by 8 p,m, while the series of sections were separated by 
180 ~m. 
~-gal Histochemistry 
Differentiated conditionally immortalized myogenic cells and muscle cry- 
ostat sections were fixed with 0.25% glutaraldehyde for 3 min and incu- 
bated  overnight at  room  temperature  with  0.4  mM X-gal  (5-bromo-4- 
chloro-3-indolyl-13-D-galactopyranoside;  Boehfinger  Mannbeim,  Laval, 
Canada) (Kinoshita et al., 1994a). Preliminary experiments indicated that 
the X-gal enzymatic histochemistry  was as sensitive as three-step immuno- 
histochemistry using monoclonal anti-13-galactosidase antibodies to local- 
ize muscle fibers formed by the fusion of donor myoblasts (not shown). 
Newborns originating from Tn-LacZ mice were tested for 13-gal expres- 
sion using the X-gal reagent, except that no fixation was necessary and in- 
cubation of a small muscle piece was performed at 37"C for 1 h. 
LAMA2 Immunohistochemistry 
Muscle sections were fixed in acetone at -20°C for 10 min and then non- 
specific Ig binding was blocked with 10% FBS in PBS for 30 rain. The rab- 
bit polyclonal anti-mouse LAMA2 (Xu et al., 1994a) was used 1/300  in 
PBS containing 1% FBS for 2 h at 37°C. The second antibody was a bioti- 
nylated goat anti-rabbit  Ig (1/100 in PBS  containing 1%  FBS  for  1  h; 
Dako,  Copenhagen,  Denmark).  The  next  step  was  incubation  with 
streptavidin-HRP or streptavidin-FITC in some cases (1/200 in PBS con- 
taining 1%  FBS;  Dako).  Binding was revealed  with  DAB  (0.5  mg/ml; 
Sigma Chemical Co.,  St.  Louis,  MO)  and  0.015%  hydrogen peroxide. 
Slides were  mounted in  PBS-glycerol.  Immunoperoxidase-positive and 
-negative fibers were counted by microscopic examination of each muscle 
on the section with the most positive fibers. 
Desmin Immunocytochemistry 
Conditionally immortalized myogenic cells were  grown on 2%  gelatin- 
coated plates and allowed to fuse in 5% FBS at 37°C. The cells were fixed 
and  permeabilized  with  methanol  at  -20°C.  Nonspecific  binding  was 
blocked using 10% FBS in PBS for 30 rain. The cells were incubated with 
a mouse anti-desmin antibody (1/50 in PBS containing 1% FBS for 1 h; 
Dako). The second antibody was FITC-conjugated rabbit anti-mouse IgG 
(1/100 in PBS containing 1% FBS for 1 h; Dako). 
Results 
Primary Muscle Cell Culture Transplantation under 
FK506 Immunosuppression 
fl-gal Expression. Primary muscle cell cultures from trans- 
genic mice expressing [5-gal under the control of a muscle- 
specific promoter were able to develop inside the TA mus- 
cles of dy/dy mice immunosuppressed with FK506. Some 
myoblasts  fused  together or  with  host  muscle  fibers  to 
form new or hybrid muscle fibers expressing [3-gal. These 
I~-gal expressing fibers were not numerous and they were 
not dispersed throughout muscles (low magnification, Fig. 
2). They were presumably located only near the injection 
sites. As seen in Table I, the percentage of 13-gal-positive 
fibers was rarely higher than 5%. These low percentages 
were obtained whatever the age of the recipient mice at 
the time of transplantation, a slight but not significant in- 
Vilquin et al. Laminin or2 Chain Restoration in dy/dy Mouse  187 Figure 2.  13-gal-positive  muscle fibers following noncompatible 
transgenic primary muscle cell culture  transplantation  in dy/dy 
mice. X-gal staining by histochemistry. The new (donor/donor) or 
hybrid  (host/donor)  13-gal expressing fibers  are less numerous 
when cells are injected in older animals without muscle pretreat- 
ment (a) than when cells are injected in younger animals after 
~/-irradiation and notexin pretreatment (b). Bar, 260 ~m. 
crease was observed when animals were kept longer after 
transplantation. 
LAMA2~:l~ression.  As  previously  reported,  LAMA2 
was  absent  from muscles of dy/dy mice (Arahata  et al., 
1993; Sunada et al., 1994; Xu et al., 1994a,b) and was never 
expressed in muscles only injected with HBSS (Fig. 3 a). 
LAMA2  surrounded  normal  mouse  muscles  (Fig.  3  b). 
LAMA2 was expressed around some muscle fibers follow- 
ing Tn-LacZ primary muscle cell culture transplantation. 
The total and relative numbers of LAMA2-positive fibers, 
however, depended on the age of the mouse at transplan- 
tation and on the pretreatment of the muscle (Table I). 
The percentage of LAMA2-positive fibers was low (mean 
+_  SD, 6.4  +_  4.4) when older animals  (i.e., more than 3 
mo), were used as recipients (Fig. 3, c and d). The percent- 
age  of LAMA2-positive  fibers  was  higher  (15.9  +__  9.0) 
when younger animals (i.e., 6 wk old) were used as recipi- 
ents (Fig. 3, e and f). Notexin alone, or ~/-irradiation alone, 
did not increase the number of LAMA2-positive fibers. 
The  combination  use  of  notexin  and  "~-irradiation  in- 
creased the percentage of LAMA2-positive fibers in trans- 
planted muscles (27.8  ___  14.9).  There was an overall but 
not significant increase in the percentage of LAMA2-posi- 
tive fibers with the duration of the experiment (Table I, 
the mice in group A all received the same myoblast prepa- 
ration). 
Colocalization of [3-gal and LAMA2.  The Tn-LacZ primary 
muscle cultures originate from mice with normal LAMA2 
expression. Thus, both the normal gene for LAMA2 and 
the reporter gene coding for I~-gal are present in the donor 
cells. LAMA2 and 13-gal were characterized on serial sec- 
tions only spaced by 8 ~m. As shown in Table I, the per- 
centages  of  LAMA2-positive  and  l~-gal-positive  fibers 
were comparable when old animals (>3 mo) were used for 
transplantation. LAMA2 and [~-gal labeling were localized 
in the same clusters of fibers (Fig. 4). Some LAMA2-posi- 
tive fibers, however, were negative for I~-gal expression, 
and some 13-gal-positive fibers were negative for LAMA2 
expression on serial sections (Fig. 4, g and h). Most of the 
Table L Outcome of Transplantation of Transgenic Primary Muscle Cell Culture in FK506-immunosuppressed Animals 
Percent  Percent 
Mouse No.  Age at Tx  Days after Tx*  Leg  Muscle treatment  ~  Total number of fibers  I~-gal-positive  LAMA2-positive  I~-gal-positive  LAMA2-positive 
d 
A1  92  21  Left  None  1,655  53  85  3.2  5.1 
A2  92  21  Left  None  1,187  88  97  7.4  8.2 
A3  92  21  Left  None  1,165  28  45  2.4  3.9 
Right  Notexin  875  5  55  0.6  6.3 
A4  92  21  Left  None  774  15  24  1.9  3.1 
A5  92  39  Left  Notexin  920  58  128  6.3  13.7 
A6  92  39  Left  None  1,125  103  165  9.1  14.7 
A7  92  39  Left  None  1,277  25  47  1.9  3.7 
B1  45  27  Left  ~/+ Notexin  932  3  162  0.3  17.4 
Right  None  1,454  70  204  4.8  14 
B2  45  27  Left  ~/+ Notexin  1,161  51  511  4.4  44 
Right  None  1,375  58  355  4.2  25.8 
B3  45  27  Left  ~  +  Notexin  1,505  85  285  5.6  18.9 
Right  None  1,468  48  118  3.3  8 
B4  45  27  Left  ~/  502  24  97  4.8  19.3 
Right  Notexin  895  8  115  0.9  12.8 
B5  45  27  Left  ~/  651  2  101  0.3  15.5 
Right  Notexin  953  21  193  2.2  20.3 
Cultured cells were injected in one or both TA at the ages indicated, with or without muscle pretreatment. At the times indicated, the mice were sacrificed. The I~-gal-  and 
LAMA2-positive  fibers were counted on the best section. *Tx, transplantation.  *Notexin  indicates uotexin injection and 3,, 3' ray irradiation. 
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LAMA2 following noncom- 
patible  transgenic  primary 
muscle cell culture transplan- 
tation in dy/dy mice. Immu- 
noperoxidase  labeling. 
LAMA2  is  not  present  in 
non-injected or sham-injected 
dy/dy muscles (a) whereas it 
surrounds  all  the muscle  fi- 
bers  in  normal  animals  (b). 
The percentage of LAMA2- 
positive  fibers  is  low  when 
cells are injected in older ani- 
mals  without  pretreatment 
(c)  or notexin pretreatment 
alone (d). The use of younger 
animals  increases  the  per- 
centage  of LAMA2-positive 
fibers  without  pretreatment 
(e) or after ~-irradiation  and 
notexin pretreatment  (39. Bar, 
260 I~m. 
smallest fibers were 13-gal positive. These results indicated 
either that [3-gal and LAMA2 expression were not regu- 
lated similarly, or that the same type of cells were not re- 
sponsible for their expression. 
When  experiments were  designed  in  younger animals 
(i.e.,  6  wk  old),  the  LAMA2-positive  fibers were  much 
more abundant than [3-gal-positive fibers (Table I). Sur- 
prisingly, the pattern and intensity of 13-gal and LAMA2 
expression greatly differed. Some LAMA2-positive clus- 
ters of fibers were totally devoid of [3-gal (Fig. 4, a-f). The 
[3-gal-positive fibers were restricted to smaller areas than 
LAMA2-surrounded fibers. LAMA2-positive fibers were 
observed over long distances throughout the muscle, i.e., 
more than  1,000  I~m, whereas no 13-gal was  observed in 
most of these fibers over all length of LAMA2 expression 
(Fig. 4, a-f). 
Long-term Histocompatible Transplantations 
Transplantation  of  histocompatible,  isogenic  primary 
mouse  muscle  cells  in  6-wk-old male dy/dy  mice led  to 
long-term LAMA2 expression (i.e., 11  wk)  in the trans- 
planted  muscles  of  all  the  animals.  The  percentage  of 
LAMA2-positive muscles was greater when muscles were 
treated using notexin and ~/-irradiation before transplanta- 
tion (14.75 _+ 6.4 without pretreatment versus 41.2 _-+ 14.3 
with pretreatment). Notexin alone (12.75 --+ 1.2 positive fi- 
bers), or irradiation alone (19.25 ___ 6.9 positive fibers), fol- 
lowed by transplantation,  was  not  sufficient to  increase 
dramatically  the  percentage  of  LAMA2-positive  fibers 
(Table Ii, Fig. 5, a and b). Given the small number of dy/ 
dy mice available for these experiments, however, no sta- 
tistical analysis was performed. 
LAMA2 seemed to have spread centrifugally from the 
injection site (Fig. 5, e and f). While LAMA2 completely 
surrounded normal mouse muscle  fibers, its localization 
was frequently incomplete and disrupted in transplanted 
dy/dy muscles, especially in case of the largest fibers (Fig. 
5, g and h). Thus, LAMA2 deposition seemed to be local- 
ized (Fig. 5, f  and g). LAMA2 deposition also presented 
important variations in transplanted mice as compared to 
normal mice. Most of the smallest fibers were totally sur- 
rounded by LAMA2 (Fig. 5 g). 
The use of ~/-irradiation and notexin induced some dam- 
ages into the muscles (Fig. 4, a-f; Fig. 5 b), that were more 
pronounced in the long-term experiments. As previously 
Vilquin et al, Laminin ct2 Chain Restoration in dy/dy Mouse  189 Figure 4.  13-gal  and LAMA2 coexpression in serial sections following noncompatible transgenic primary muscle cell transplantation  in 
dy/dy mice. X-gal histochemistry (left) and LAMA2 immunohistochemistry  (right).  13-gal-positive clusters (a, c, and e, arrowheads)  are 
less numerous than LAMA2-positive clusters (b, d, and f, asterisks).  On low magnification pictures, I~-gal-positive fibers are also 
LAMA2-positive, whereas LAMA2-positive are not always 13-gal positive; a and c are spaced by 180 g~m; a and e are spaced by 1,080 
p~m. At higher magnification  of new or hybrid fibers (g and h), some LAMA2-positive  fibers (h, asterisks) do not express I~-gal,  whereas 
some B-gal-positive fibers (g, arrowheads) do not express LAMA2. Bars: (a-f) 20 Ixm; (g and h) 80 ~m. Figure 5.  LAMA2 expression pattern in long-term histocompatible transplantation model. LAMA2 immunoperoxidase labeling (a, b, e, 
g, and h), hematoxylin-eosin staining (c and d), FITC immunostaining (f). The percentage of LAMA2-positive fibers is higher after ~-irradi- 
ation and notexin pretreatment (b) than without pretreatment (a). Note that ~-irradiation and notexin pretreatment induce muscle dam- 
ages (b) that are particularly evident in long-term experiments. Noninjected and nonpretreated muscle of 4-mo-old dy/dy mouse, how- 
ever, shows extensive fibrosis, infiltration, and the muscle fiber size, shape and distribution are variable (c). Compare to the TA muscle 
from a normal mouse (d). The pictures e and f show that LAMA2 is present at the injection sites in a centrifugal manner, that is, cells at 
the periphery are less positive than cells in the center, or positive in part of their perimeter. In g (high magnification of e, asterisks locate 
the same fibers), LAMA2 is only present at the side of the fiber facing the center of injection site (arrows). The thickness of the immu- 
nolabeling for LAMA2 is variable, as compared to normal mouse muscle (h). Bars: (a-d) 290 p~m; (e and f) 115 Ixm; and (g and h) 55 ~m. 
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Percent 
Age at  Days  Muscle  Total Number  LAMA2-  LAMA2- 
Mouse No.  Tx*  after Tx  Leg  treatment  ~  of fibers  positive  positive 
d 
H 1  45  77  Left  ",/  1,238  178  14.4 
Right  Notexin  1,655  225  13.6 
H2  45  77  Left  -¢  1,396  336  24.1 
Right  Notexin  1,475  175  11.9 
H3  45  77  Left  3' +  Notexin  1,007  517  51.3 
Right  None  942  182  19.3 
H4  45  77  Left  3' +  Notexin  711  221  3 I. 1 
Right  None  1,280  130  10.2 
Cell cultures were injected in both legs after muscle pretreatment.  The mice were killed 11 weeks after transplantation,  and LAMA2-positive  fibers were counted on the best sec- 
tion. *  Tx, transplantation. *  Notexin indicates notexin injection, and 3', ~' ray irradiation. 
described in the mdx/mdx mouse model, the dy/dy muscle 
weight was significatively decreased by 30% (mean weight, 
no pretreatment, 17 _+ 2 mg; -,/-irradiation and notexin 12 
_  2 mg; P  <  0.004). It should be noted, however, that dy/ 
dy muscles already show extensive fibrosis and cellular in- 
filtration in  the  absence  of irradiation  and  notexin pre- 
treatment (Fig. 5, c and d). 
Conditionally Immortalized Myoblast Culture 
Transplantation under FK506 Immunosuppression 
Characterization of Immortalized Myogenic Cell Lines. 
The  problem  of tumorigenicity  was  frequently  reported 
upon the use of the classical C2 mouse myoblast cell line 
(Wernig et al., 1991; Morgan et al., 1992). Thus, Morgan et 
Figure 6.  In vitro and in vivo characterization of conditionally immortalized myogenic cells. Most of the myogenic cells (a, clone MB7) 
express desmin (b, clone MB7) after some hours upon passage into differentiation medium. 3 d after passage in differentiation medium, 
these cells fuse and differentiate into myotubes which express the 13-gal transgene (c, clone MB27). The myogenic cells participate in the 
formation of new or hybrid muscle fibers when injected into immunodeficient SCID mice (d,  1 mo after cell transplantation of clone 
MB27). Bars: (a and b) 30 ixm; (c) 45 I~m; and (d) 100 Ixm. 
The Journal of Cell Biology, Volume 133, 1996  192 Figure 7.  Injections of pure myogenic cells into dy/dy muscles. X-gal histochemistry (a, c, and e) and LAMA2 FITC immunostaining (b, 
d, and f). When injected into left dy/dy TA, myogenic clone MB27 is able to form 13-gal-positive new or hybrid fibers (a). These fibers 
are not surrounded by LAMA2 on an adjacent section (b, asterisk locate the same fiber). When clone MB3 is injected into dy/dy mus- 
cles, t3-gal-positive  new or hybrid fibers are formed (c); a very faint LAMA2 labeling could be observed around two fibers (d, arrow- 
heads) out of which only one is 13-gal  positive.  When clone MB27 is injected together with compatible primary muscle cell culture in the 
right TA, 13-gal-positive fibers are formed (e) and LAMA2 expression is observed at the injection site  (f) around 13-gal-positive and 
-negative fibers on adjacent sections (asterisks  locate the same fiber).  Bar, 100 ~m. 
al. (1994) developed a technique to obtain pure, immortal- 
ized myoblast clones with the ability to form new muscle 
fibers after transplantation  into immunodeficient and dys- 
trophin-deficient  nu/mdx mice,  without inducing  tumors. 
The transgenic myoblast cultures developed in the present 
study  have  the  additional  advantage  that  differentiated 
cells express  13-gal under the control of a  specific muscle 
promoter.  This  allows  the  rapid  identification  of new  or 
hybrid fibers formed by the fusion of these  myoblasts in 
vitro or in vivo in any mouse model. 
The  muscle  cells  isolated  as  colonies  or  single  clones 
from  newborn  muscles  of  (Tn-LacZ)  X  (H-2Kb-tsA58) 
mice were able to grow and proliferate  at 33°C in a  10% 
CO2 atmosphere when stimulated by murine IFN-% When 
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In vitro characterization  Injection in left leg*  Injection in right leg* 
Desmin  [3-gal  LAMA2-  13-gal-  LAMA2-  13-gai- 
Cell culture  Passage No.  expression  expression  positive  positive  positive  positive 
n §  nil  n ~  nil 
MB3  9  pos (>95%)  myotubes  0 (I)~  0 (1)  ND  ND 
MB7  7  pos (>95%)  myotubes  0 (3)  ~1  3 (3)  2 (2)  2 (2) 
Colony No. 24  4  pos (>90%)  myotubes  0 (1)  0 (1)  1 (1)  1 (1) 
MB27  8  pos (>90%)  myotubes  0 (3)  3 (3)  3 (3)  3 (3) 
Myogenic cells were selected in vitro based on desmin expression and the ability to form 13-gal-positive myotubes in differentiation medium. The cells were injected in FK506- 
immunosuppressed, 4--8-wk-old dy mice with or without addition of primary muscle cell culture, 2, 3, or 4 wk later the mice were sacrificed. [3-gal and LAMA2 expression were 
investigated on adjacent sections. Typical [3-gal and LAMA2 expression are presented in Pig. 6. 
* Only the myogenic clone or colony injected. *Myogenic clone or colony injected together with primary muscle cell culture. ~Number of mice expressing LAMA2; (n) total num- 
ber of mice in one experiment. IINumber  of mice expressing 13-gal; (n) total number of mice in one experiment. S2or 3 fibers were faintly surrounded. ND: not done. 
shifted to differentiation medium the muscle cells fused 
together and formed giant myotubes. These cells, either 
myotubes or myoblasts alone, expressed the intracellular 
filament desmin, which is  an early marker of myoblasts 
(Fig. 6, a and b) (Lin et al., 1994). The myotubes and some 
early differentiated myoblasts expressed also 13-gal (Fig. 6 
c). The cells were able to fuse and to form new or hybrid 
muscle fibers expressing [~-gal in vivo in immunodeficient 
SCID mice without forming solid tumors (Fig. 6 d). The 
colony No. 24 (two cells in the original cloning well) and 
the clones MB3, MB7 and MB27 were selected based on 
their in vitro myogenic characteristics and were injected 
into dy/dy muscles. 
Lack of LAMA2 Expression Despite Muscle Fiber Forma- 
tion after Myoblast Clone Transplantations. 2, 3, and 4 wk 
after  injection  of  conditionally  immortalized  myoblast 
clones into left TA of dy/dy mouse, some [3-gal positive fi- 
bers  were  formed  (Fig.  7,  a  and c,  respectively, clones 
MB27 and MB3, and Table III). The number of f3-gal pos- 
itive fibers was low possibly because the muscles were not 
pretreated with notexin and irradiation. On adjacent sec- 
tions, however, essentially no LAMA2 could be detected 
in the same TA muscle, neither surrounding [3-gal-positive 
fibers  or  [3-gal-negative  fibers  (Fig.  7  b,  clone  MB27). 
LAMA2 was also absent from the series of sections pre- 
ceeding and succeeding ~-gal-positive sections, thus indi- 
cating that a putative difference in the restriction domain 
of LAMA2 and 13-gal was not responsible for the lack of 
LAMA2 expression in this model. A  very faint labeling 
could be observed around some, but not all muscle fibers 
(Fig. 7 d, clone MB3) and some of these faintly positive fi- 
bers were [3-gal negative. Pure myoblasts were thus able to 
fuse  together or with host  muscle  fibers  and to  trigger 
[3-gal expression, but in most of the cases they did not trig- 
ger LAMA2 formation or extracellular deposition at least 
at levels detectable by immunohistochemistry or immuno- 
histofluorescence (Table III), The right dy/dy TA of the 
same mouse, which was injected with a classical histocom- 
patible primary cell culture together with the same myo- 
genic clone  MB27,  however,  contained many LAMA2- 
surrounded muscle fibers and/or [3-gal-positive fibers (Fig. 
7, e and f). The 13-gal and LAMA2 proteins were not al- 
ways located in and around the same fibers. 
Lack of LAMA2 Expression after Fibroblast Permanent 
Cell Lines Transplantations. Permanent fibroblast cell lines 
$3T3 and BLK CL.4 (both from American Type Culture 
Collection) were transplanted into dy/dy mice but did not 
induce LAMA2 production (data not shown). These fibro- 
blast lines, however, may not be representative of all cell 
types obtained in a primary muscle cell culture. 
Discussion 
Overall Transplantation Success 
Three transplantation models were used in this study. In 
the first one, nonhistocompatible primary muscle cells ex- 
pressing the 13-gal under control of a muscular promoter 
were transplanted into dy/dy  mice. This allogenic trans- 
plantation required an efficient immunosuppression, which 
was obtained using FK506 (Kinoshita et al., 1994b; Vilquin 
et al., 1995b). The use of 13-gal expressing cells showed the 
exogenous origin of the labeled muscle fibers and allowed 
the comparison between LAMA2 and [3-gal localization 
after transplantation. In the second model, histocompati- 
ble  syngeneic primary cultures  from normal littermates 
were transplanted into dy/dy mice. This model did not re- 
quire immunosuppression and allowed the study of muscle 
regeneration over longer time. In the third model, pure 
but nonhistocompatible myoblasts were transplanted into 
one leg of FK506-immunosuppressed dy/dy mice, whereas 
the other leg received histocompatible primary culture as 
a control of LAMA2 expression. This model allowed the 
direct comparison of the outcome of transplantation be- 
tween  pure  myoblast and  primary muscle  cells  and  al- 
lowed the investigation of the potential role of myoblasts 
in LAMA2 deposition. 
Cell transplantation allowed the restoration of a struc- 
tural, extracellular protein. In these immunologically con- 
trolled models the transplantation of primary muscle cells 
led to LAMA2 expression in variable amounts in all ani- 
mals.  The  number  of  LAMA2-surrounded  fibers  was 
shown to depend on the age of the animal at the time of 
transplantation and on the muscle pretreatment. The high- 
est numbers of LAMA2-surrounded fibers were obtained 
when young animals (6 wk old) received histocompatible 
cells after ",/-irradiation  and notexin pretreatment of the 
muscle. Irradiation was shown to hamper myoblast prolif- 
eration and thus reduce normal muscle regeneration, and 
to favor extensive fibrosis in dy/dy (Wirtz et al., 1982) and 
mdx/mdx  (Wakeford  et  al.,  1991)  mice.  This  treatment 
greatly increased donor myoblast permeation into host de- 
generating fibers and the formation of new or hybrid dys- 
trophin-positive fibers in mdx/mdx mice (Morgan et al., 
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notexin necrosis initially favor donor cell development in 
vivo over the dy/dy recipient cells. 
In  the  histocompatible  model  LAMA2,  which  is  the 
only known difference between dy/dy host mice and  +/? 
donor mice, is not sufficient to trigger efficient acute rejec- 
tion  of LAMA2-expressing cells.  Interestingly, the  mice 
did not produce antibodies directed against LAMA2 (not 
shown). Chronic rejection was not assessed in this study, 
but  the  overall  highest  numbers  and  percentages  of 
LAMA2-surrounded fibers were observed after the long- 
est survival time (i.e., 11 wk after grafting). LAMA2 is un- 
dectable in immunohistochemistry but very low amounts 
of LAMA2 mRNA are detected in untreated dy/dy mice 
by RT-PCR (Arahata et al.,  1993;  Xu et al., 1994a). The 
reason  why  the  transplanted  animals  are  tolerant  to 
LAMA2 is not known. 
The intensity of [3-gal staining and the number of 13-gal- 
positive fibers after transgenic Tn-LacZ culture transplan- 
tation was low as compared to results obtained in other, 
non dy/dy mice strains under the same FK506 immunosup- 
pressive  treatment.  In  a  previous report,  up  to  90%  of 
mdx/mdx TA muscle fibers could express 13-gal only one 
month after transplantation (Kinoshita et al., 1994b). The 
present results suggest that muscle cell transplantation is 
less efficient in dy/dy mouse than in mdx. Actually, more 
than  1,000  dystrophin-positive fibers  are  frequently ob- 
tained in only 2 mo after histocompatible primary muscle 
culture transplantation in mdx/mdx  mice (Vilquin et al., 
1995c), whereas it is difficult to obtain more than 300 to 
400 LAMA2-surrounded muscle fibers in the same time in 
dy/dy  mice. The humoral  and cellular immune reactions 
against  [3-gal and MHC proteins are very efficiently con- 
trolled by FKS06 in various transplantation models, ani- 
mals, or mouse strains (Kinoshita et al., 1994b, 1995; Asse- 
lin  et  al.,  1995;  Vilquin  et  al.,  1995b,c).  Thus,  immune 
rejection is not likely to be the cause of the relatively poor 
cellular engraftment in immunosuppressed dy/dy mouse as 
compared to mdx/mdx mouse. The dy/dy muscle fibers are 
smaller than normal muscle fibers and they show impor- 
tant size variation within a single muscle (Michelson et al., 
1955;  see also Fig.  5, c  and  d).  This may reflect trophic 
problems  in  dy/dy  muscles  related  to  the  absence  of 
LAMA2 in basal lamina that could explain the variation in 
regeneration efficiency between the mdx/mdx and the dy/ 
dy models. First, the initial lack of LAMA2 could hamper 
myoblast migration or alignment either with other myo- 
blasts or with host muscle fibers, because basal lamina is 
known to play important roles in the control of migration, 
proliferation and differentiation of various cell types (Eng- 
vail et al., 1992). Thus, the lack of LAMA2 could hamper 
regeneration. Muscle  regeneration could depend  on the 
presence of a pre-existing complete basal lamina. Second, 
an  impaired  muscle  innervation  due  to  the  absence  of 
LAMA2 around peripheral nerve fibers or neuromuscular 
junctions (Leivo and Engvall, 1988; Sunada et al., 1994; Xu 
et  al.,  1994a)  could induce a  muscle  atrophy. Third, the 
myoblast proliferation and/or migration could be impaired 
by the abundant connective tissues, present especially in 
the  oldest  dy/dy  mice.  Taken  together,  these  problems 
may explain why muscle regeneration was relatively poor 
following transplantation, whatever the pretreatment used. 
LAMA2 and fl-gal Colocalization  after Transplantation 
of Transgenic Primary Cells 
In  transplanted  muscle,  LAMA2  was  generally  more 
widely distributed than 13-gal. This could indicate differ- 
ences in the regulation of expression of these two proteins, 
that LAMA2 but not 13-gal can diffuse extracellularly, or 
that the cell type responsible for LAMA2 expression is not 
the cell type responsible for [3-gal expression. Although 
the [3-gal gene in the TnI-LacZ1/29 mice is under the con- 
trol of the promoter of the quail fast troponinI, the [3-gal 
was reported to be expressed in all fiber types by Hallauer 
et al.  (1993). Moreover, transgenic [3-gal myoblast trans- 
plantation into the TA of mdx/mdx mice under FK506 im- 
munosuppression was reported to lead to the strong ex- 
pression of t3-gal in as much as 90%  of the fibers within 
one  month,  thus  probably including both  fast  and  slow 
muscle fibers (Kinoshita et al., 1994b). 13-gal expression is 
restricted to skeletal muscle cells as an intracellular pro- 
tein, and its nuclear domain is ~1,000 ~m (Kinoshita, I., 
personal results). In contrast, laminins and likely LAMA2 
are secreted outside of the cells, and may have a relatively 
long  half-life  in  vivo (Engvall,  1993)  as  components  of 
muscle  cells  basal  lamina.  Thus,  the  fate  of  [3-gal and 
LAMA2 in vivo is probably different. Whereas [3-gal ex- 
pression requires myoblast fusion and formation of hybrid 
or new muscle fibers, the developmental mechanisms  of 
LAMA2 expression are still unclear. 
[3-gal  and  LAMA2  did  not  always  colocalize in  and 
around the same segments of muscle fibers. On serial sec- 
tions 13-gal-positive segments of fibers could be LAMA2 
negative and vice versa. Thus, either myoblasts and muscle 
fibers do express both [3-gal and LAMA2, or these pro- 
teins are expressed by several or only partially overlapping 
different cell types, or by cells at different stages of differ- 
entiation. If muscle cells express both LAMA2 and [3-gal, 
then 13-gal-positive fibers should be surrounded by LAMA2, 
even on short muscle fiber segments. This was not always 
observed. The other hypothesis implies that myoblasts and 
muscle  fibers  should  express  13-gal, whereas  other  cells 
should secrete LAMA2. Depending on the presence and 
development of myoblasts, or LAMA2-secreting cell, or 
both cell types in the vicinity of host muscle fibers after 
transplantation of primary muscle cell culture, t3-gal-posi- 
tive, or LAMA2 positive, or both 13-gal- and LAMA2-pos- 
itive fibers should be observed. 
LAMA2 Expression Pattern 
LAMA2  generally deposited continuously around  small 
caliber  muscle  fibers,  whereas  this  deposition  was  fre- 
quently discontinuous around normal diameter muscle fi- 
bers, even two months after transplantation (Fig. 5, e and 
f). In contrast, dystrophin was expressed along the com- 
plete inner circumference of muscle fibers by some weeks 
after transplantation, and dystrophin disruption was rarely 
observed one or several months after transplantation  in 
the  mdx/mdx  or  SCID  mouse  models  (Partridge  et  al., 
1989; Morgan et al., 1990,  1993,  1994; Huard et al., 1994; 
Kinoshita et al.,  1994b; Vilquin et al., 1995c). The expres- 
sion of LAMA2 seemed to occur in a radial manner from 
the site of injection. This observation suggests that compe- 
tent cells could proliferate and diffuse, or that the secre- 
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LAMA2 expression that would progressively accumulate 
around the most proximal muscle fibers. 
Role of  Myoblasts in LAMA2 Restoration in 
dyldy Mice 
Cloned myogenic cells formed new or hybrid [3-gal-posi- 
rive  muscle  fibers  following  transplantation  into  dy/dy 
mice. Small and normal caliber [3-gal-positive fibers were 
obtained already 2 wk after transplantation. Small-caliber 
fibers were likely entirely of donor origin. Normal-caliber 
fibers probably originated from the fusion of donor myo- 
blasts with host muscle fibers undergoing a segmental de- 
generation-regeneration process  at  the  site  of injection. 
The 13-gal-positive fibers, however, were very rarely sur- 
rounded by LAMA2, thus indicating that myoblasts and 
muscle  fibers formed by them were  not  able  to  secrete 
LAMA2,  at  least  to  levels  detectable  by  immunohis- 
tochemistry and  immunohistofluorescence. As  a  control 
for LAMA2 expression, primary cells from mixed cultures 
injected  in  the  contralateral  leg  were  able  to  trigger 
LAMA2 deposition around new and hybrid muscle fibers 
within 2 wk. Thus, LAMA2 may be secreted by some com- 
petent cells present in primary culture, but not in cloned 
myoblasts. Another hypothesis which cannot be ruled out 
yet, is that none of the myogenic clones used in this study 
was able to produce LAMA2 in vivo, despite their ability 
to express desmin, to express [3-gal under control of a mus- 
cular promoter, to  form myotubes in  vitro and  to form 
muscle fibers in vivo. Indeed, some distinct populations of 
satellite cells have been described in regenerating rat skel- 
etal  muscle  (Rantanen  et  al.,  1995).  The  secretion  of 
LAMA2 could be dependent on cell differentiation status 
and could be regulated in myogenic cells, as are other mus- 
cle proteins and myogenic factors (Rantanen et al., 1995). 
This hypothesis would be supported by the very faint la- 
beling observed around 2 or 3, but not all,  muscle fibers 
following clone MB3 and clone MB7 transplantation, and 
is currently under investigation. 
Future Prospects 
The transplantation models and results presented in this 
article should prove useful to study in vivo interactions be- 
tween muscle cells and  extracellular matrix. The critical 
steps for normal and pathologic muscle regeneration, that 
is, myoblast proliferation, alignment or fusion, or the sta- 
bility  of  nerve-muscle  regulations,  should  be  discrimi- 
nated. 
The  identification  of  the  cell  type  responsible  for 
LAMA2 secretion and its relation with other muscle con- 
stituents are important future issues, and could help to cat- 
egorize clinical cases of CMD and develop new strategies 
for the correction of muscular diseases by gene comple- 
mentation.  Long-term  experiments  should  also  be  de- 
signed  to improve the  transplantation  results.  The leas- 
ability of myelination restoration in the peripheral nervous 
system of the dy/dy  mouse should be  assessed  (Bradley 
and Jenkison, 1973; Sunada et al., 1995). Alternatively, the 
transducibility of the LAMA2-secreting cell type by differ- 
ent  gene  vectors  (adenoviruses,  retroviruses,  herpesvi- 
ruses) should indicate if it could constitute a good target 
candidate for in vivo or ex vivo gene therapy of CMD. 
Pancreatic islet cells, embryonic neurons, myoblasts, he- 
matopoietic bone marrow stem cells transplantations  are 
currently investigated as potential avenues for the treat- 
ment of inherited or acquired diseases. Only further stud- 
ies will indicate if some extracellular matrix pathologies 
could be rescued by cell transplantation. 
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